To assess the effect of 0.01% atropine on myopia progression, considering age and sex differences.
Methods
In this prospective study, 51 participants were enrolled in the atropine group and 48 in the control group. One in the atropine group discontinued due to allergic conjunctivitis, leaving 50 for analysis. Participants were aged 6–16 years, with a mean age of 11.1 ± 2.6 years (atropine) and 10.9 ± 2.3 years (control), and had myopia between −2.00 and −6.00 D. Subjects were categorized by age (6–9, 10–12, 13–16 years) and sex. Spherical equivalent (SE), axial length (AL, via biometry), simulated keratometry (SimK) (via topography), and pupil diameter (via topography) were measured at baseline and at 1, 3, 6, and 12 months.
Results
Baseline characteristics did not differ significantly between groups (p > .05). SE progression at 12 months was significantly lower in the atropine group (−0.16 ± 0.35 D) than in controls (−0.31 ± 0.35 D; p = .041). AL increase was significant at 6 months in the atropine group (0.1 ± 0.23 mm, p = .003) and at 12 months in both groups (atropine: 0.26 ± 0.33 mm, p < .001; control: 0.37 ± 0.7 mm, p = .001). Pupil diameter and SimK changes were more pronounced in the atropine group (p < .05).
Conclusion
Topical 0.01% atropine slows myopia progression, especially in older children. Higher doses may be more effective for younger children and females.
WuPCChuangMNChoiJ, et al.Update in myopia and treatment strategy of atropine use in myopia control. Eye2019; 33: 3–13.
2.
HoldenBMariottiSKocurI. THE IMPACT OF MYOPIA AND HIGH MYOPIA. Report of the Joint World Health Organization–Brien Holden Vision Institute Global Scientific Meeting on Myopia. 2015.
3.
HoldenBFrickeTRWilsonDA, et al.Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology2016; 123: 1036–1042.
4.
FrickeTRHoldenBWilsonDA, et al.Global cost of correcting vision impairment from uncorrected refractive error. Bull World Health Organ2012; 90: 728–738.
5.
TranHDTranYHTranTD, et al.A review of myopia control with atropine. J Ocul Pharmacol Ther2018; 34: 374–379.
6.
ShinojimaANegishiKTsubotaK, et al.Multiple factors causing myopia and the possible treatments: a Mini review. Front Public Health2022: 10.
7.
TroiloDSmithELNicklaDL, et al.IMI-Report on experimental models of emmetropization and myopia. Invest Ophthalmol Visual Sci2019; 60: M31–M88.
8.
ChuaWHBalakrishnanVChanYH, et al.Atropine for the treatment of childhood myopia. Ophthalmology2006; 113: 2285–2291.
9.
ChiaAChuaWHCheungYB, et al.Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology2012; 119: 347–354.
10.
ClarkTYClarkRA. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. J Ocul Pharmacol Ther2015; 31: 541–545.
11.
YamJCJiangYTangSM, et al.Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology2019; 126: 113–124.
12.
FuAStapletonFWeiL, et al.Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol2020; 104: 1535–1541.
13.
Azuara-BlancoALoganNStrangN, et al.Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomized trial in the UK (CHAMP-UK)-study protocol. Br J Ophthalmol2020; 104: 950–955.
14.
LeeSSYLinghamGBlaszkowskaM, et al.Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial. Clin Experiment Ophthalmol2022; 50: 1001–1012.
15.
LoughmanJKobia-AcquahELinghamG, et al.Myopia outcome study of atropine in children: Two-year result of daily 001% atropine in a European population. Acta Ophthalmol2024; 102: e245–e256.
16.
LiFFZhangYZhangX, et al.Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: low-concentration atropine for myopia progression study. Ophthalmology2021; 128: 1180–1187.
17.
MoonJSShinSY. The diluted atropine for inhibition of myopia progression in Korean children. Int J Ophthalmol2018; 11: 1657–1662.
18.
HuangJMuttiDOJones-JordanLA, et al.Bifocal and atropine in myopia (BAM) study: baseline data and methods. Optom Vis Sci2019; 96: 335–344.
19.
WallineJJ. Myopia control: a review. Eye &Contact Lens2016; 42: 3–8.
20.
Diaz-LlopisMPinazo-DuránMD. Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness. Archivos de la Sociedad Española de Oftalmología (Engl Ed)2018; 93: 182–185.
21.
LeoSW. Current approaches to myopia control. Curr Opin Ophthalmol2017; 28: 267–275.
22.
SacchiMSerafinoMVillaniE, et al.Efficacy of atropine 0.01% for the treatment of childhood myopia in European participants. Acta Ophthalmol (Copenh)2019; 97: e1136–e1140.
23.
GongQJanowskiMLuoM, et al.Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. JAMA Ophthalmol2017; 135: 624–630.
24.
ShihKCChanTCYNgALK, et al.Use of atropine for prevention of childhood myopia progression in clinical practice. Eye Contact Lens2016; 42: 16–23.
25.
MorganIGHeM. An important step forward in myopia prevention: low-dose atropine. Ophthalmology2016; 123: 232–233.
26.
FuAStapletonFWeiL, et al.Risk factors for rapid axial length elongation with low concentration atropine for myopia control. Sci Rep2021; 11: 1–7.
27.
TidemanJWLPollingJRVingerlingJR, et al.Axial length growth and the risk of developing myopia in European children. Acta Ophthalmol (Copenh)2018; 96: 301–309.
28.
ItoiMItoiM. Axial length elongation in Japanese youth with myopia. Eye& Contact Lens2021; 47: 104–107.
29.
DonovanLSankaridurgPHoA, et al.Myopia progression rates in urban children wearing single-vision spectacles. Optom Vis Sci2012; 89: 27–32.
30.
ZhouWJZhangYYLiH, et al.Five-year progression of refractive errors and incidence of myopia in school-aged children in western China. J Epidemiol2016; 26: 386–395.
31.
SunJZhouJZhaoP, et al.High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai. Invest Ophthalmol Visual Sci2012; 53: 7504–7509.
32.
MuttiDOMitchellGLHayesJR, et al.Accommodative lag before and after the onset of myopia. Invest Ophthalmol Visual Sci2006; 47: 837–846.
33.
CzepitaMCzepitaDSafranowK, et al.Role of gender in the prevalence of myopia among Polish schoolchildrenJ Ophthalmol2019; 2: 9748576.
34.
GongJFXieHLMaoXJ, et al.Relevant factors of estrogen changes of myopia in adolescent females. Chin Med J2015; 128: 659–663.
35.
LiFFKamKWZhangY, et al.Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: low-concentration atropine for myopia progression study. Ophthalmology2020; 127: 1603–1611.
36.
CooperJEisenbergNSchulmanE, et al.Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci2013; 90: 1467–1472.
37.
VerkicharlaPKKammariPDasAV. Myopia progression varies with age and severity of myopia. PLoS One2020; 15: e0241759.
